Ascendiant Capital Markets Reaffirms Buy Rating for Vivos Therapeutics (NASDAQ:VVOS)

Vivos Therapeutics (NASDAQ:VVOS)‘s stock had its “buy” rating reiterated by stock analysts at Ascendiant Capital Markets in a research note issued on Wednesday,Benzinga reports. They presently have a $6.60 price target on the stock. Ascendiant Capital Markets’ price objective suggests a potential upside of 133.22% from the company’s current price.

Separately, Alliance Global Partners cut their target price on Vivos Therapeutics from $8.25 to $6.00 and set a “buy” rating on the stock in a research note on Tuesday.

Vivos Therapeutics Price Performance

NASDAQ VVOS opened at $2.83 on Wednesday. The company has a fifty day moving average price of $2.78 and a 200-day moving average price of $2.52. Vivos Therapeutics has a 1 year low of $1.91 and a 1 year high of $48.79. The firm has a market cap of $13.48 million, a price-to-earnings ratio of -0.50 and a beta of 7.71.

Vivos Therapeutics Company Profile

Vivos Therapeutics, Inc, a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring.